CAR-based Cellular Therapy: clinical ePoster

A098 - CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (ID 924)

Authors
  • H. Huang
  • S. Liu
  • Q. Zhu
  • Y. Duan
  • D. Wu

Abstract

Background:
Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment modality that highly effective in the treatment of relapse/refractory
B-cell lymphoma, providing alternative therapeutic options for patients who failed to respond to conventional treatment or relapse. Although highly remission rates have been reported with
CAR-T cell therapy in relapse/refractory B-cell lymphoma, relapse or disease progression is common after CAR-T therapy. This current study is to better our understanding of whether consolidative hematopoietic stem cell transplantation(HSCT) confers superior survival outcomes to patients who got remission by CAR-T cells therapy.

Methods:
Compare the efficacy and survival of CAR-T therapy followed by HSCT and CAR-T alone in patients with relapsed/refractory B-cell lymphoma. 30 cases with CR or PR disesse status after CAR-T cells therapy in the First Affiliated Hospital of Soochow University from 2017 to 2019 were included. 11 of these cases (36.7%) were treated with HSCT after CAR-T therapy, of which 7 cases were treated with autologous stem cell lymphoma(ASCT), and 4 cases were treated with allogeneic stem cell transplantation(Allo-SCT). 19 of these cases (63.3%) were treated with CAR-T only. Overall survival(OS) and progression-free survival(PFS) rates were estimated by the Kaplan-Meier method, and Survival comparison was analyzed by using the log-rank test.

Results:
Kaplan-Meier survival curve indicated that PFS of the HSCT following CAR-T group were higher than the CAR-T group, and log rank test showed that the difference of survival curve was statistically significant (P = 0.044). The estimated 1-year and 2-year progression-free survival(PFS)were 90.9%and 50% respectively in the CAR-T followed by HSCT group. The estimated 1-year and 2-year progression-free survival(PFS)were 71.6% and 27.8% respectively in the CAR-T group. Kaplan-Meier survival curve analysis indicated that OS of the HSCT following CAR-T group were higher than the CAR-T group, while log rank test showed that the difference of survival curve was no statistically significant (P = 0.250).The estimated1-year and 2-year overall survival(OS) were 90% and 89.4% respectively in the HSCT following CAR-T group, the estimated1-year and 2-year overall survival(OS) were90%and66.2% respectively in the CAR-T group.

Conclusions:
Hematopoietic stem cell transplantation(HSCT) appear to improve progression-free survival (PFS) for the patients achieving remission following CAR-T therapy with relapse/refractory B-cell lymphoma. Future prospective studies needed to clearly define the role of consolidative HSCT in the relapse/refractory B-cell lymphoma patients who attained remission from CAR-T infusion and importantly, better identify this strategy whether exhibits superior overall survival outcomes.



[PFS AND OS]

 

Disclosure:
there is no conflict of interest or source of funding

Collapse